Hitting The Ground Running In Oncology

By Ben Comer, Chief Editor, Life Science Leader

In less than five years, Servier Pharmaceuticals, the U.S. division of Servier — the second largest French pharmaceutical company behind Sanofi — grew from 50 employees to over 400. During the same period, the company grew from one marketed product to four and from five pipeline candidates to more than 20. What began with the $2.4 billion purchase of Shire’s oncology business in 2018 has turned into an integrated organization based in Boston, which runs the gamut from basic science and drug discovery to product commercialization. With an ambitious set of growth targets, including the goal of topping $2 billion in oncology-only product revenue by 2030 and launching a new molecule, or new product indication, every year, the pressure is on to perform.